Atovaquone
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- Atovaquone
- Generic name
- ATOVAQUONE
- Manufacturer
- Camber Pharmaceuticals, Inc.
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- 2445304e-4b4e-4358-b098-31f3c49c52ef
- SPL ID
- 53e3680b-e7d0-82b4-e063-6394a90af9e8
- Version
- 5
- Effective date
- 2026-06-10
- Source export date
- 2026-11-13
- Source partition
- 4
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0004-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/2aa9706206c534e56285cf80077b2cca2320f0a236e2aa30e80d064749f7c888/drug-label-0004-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 16:00:53
| Harmonized routes |
|---|
| ORAL |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | ANDA | 210692 | derived:openfda.application_number |
| application number | ANDA210692 | openfda.application_number | |
| brand name | Atovaquone | openfda.brand_name | |
| generic name | ATOVAQUONE | openfda.generic_name | |
| manufacturer name | Camber Pharmaceuticals, Inc. | openfda.manufacturer_name | |
| ndc | package | 31722-629-21 | openfda.package_ndc |
| ndc | product | 31722-629 | openfda.product_ndc |
| ndc11 | package | 31722062921 | derived:openfda.package_ndc |
| rxcui | 308429 | openfda.rxcui | |
| spl id | 53e3680b-e7d0-82b4-e063-6394a90af9e8 | id | |
| spl set id | 2445304e-4b4e-4358-b098-31f3c49c52ef | set_id | |
| unii | Y883P1Z2LT | openfda.unii |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
5 WARNINGS AND PRECAUTIONS • Failure to administer atovaquone oral suspension with food may result in lower plasma atovaquone concentrations and may limit response to therapy. Patients with gastrointestinal disorders may have limited absorption resulting in suboptimal atovaquone concentrations. (5.1) • Hepatotoxicity: Elevated liver chemistry tests and cases of hepatitis and fatal liver failure have been reported. (5.2) • Severe Cutaneous Adverse Reactions (SCARs): Cases of SCARs such as Stevens-Johnson Syndrome (SJS) have been reported. SCARs can be life-threatening or fatal. If symptoms or signs of SCARs develop, discontinue atovaquone oral suspension immediately and institute appropriate therapy. ( 5.3 ) 5.1 Risk of Limited Oral Absorption Absorption of orally administered atovaquone oral suspension is limited but can be significantly increased when the drug is taken with food. Failure to administer atovaquone oral suspension with food may result in lower plasma atovaquone concentrations and may limit response to therapy. Consider therapy with other agents in patients who have difficulty taking atovaquone oral suspension with food or in patients who have gastrointestinal disorders that may limit absorption of oral medications [see Clinical Pharmacology (12.3)]. 5.2 Hepatotoxicity Cases of cholestatic hepatitis, elevated liver enzymes, and fatal liver failure have been reported in patients treated with atovaquone [see Adverse Reactions (6.2)]. If treating patients with severe hepatic impairment, closely monitor patients following administration of atovaquone oral suspension. 5.3 Severe Cutaneous Adverse Reactions Casesof severe cutaneous adverse reactions (SCARs), including Stevens-Johnson Syndrome (SJS), drug reaction with eosinophilia and systemicsymptoms(DRESS),and erythema multiforme (EM) have been reported in patients treated with atovaquone oral suspension [see Adverse Reactions (6.2) ]. SCARscan be life-threatening or fatal. If symptoms or signs of SCARs develop, discontinue atovaquone oral suspension immediately and instituteappropriatetherapy. Patients who have developed SCARs with theuseof atovaquone oral suspension must not receive atovaquone oral suspension [see Contraindications (4) ].
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions table
<table cellspacing="0" cellpadding="0" border="0" width="754.11"><col width="31.7460317460317%"/><col width="34.7442680776014%"/><col width="33.5097001763668%"/><tbody><tr styleCode="Botrule"><td align="justify" styleCode="Lrule Rrule" valign="top"> <content styleCode="bold">Adverse Reaction</content> </td><td align="center" styleCode="Rrule" valign="top"><content styleCode="bold">Atovaquone Tablets</content> <content styleCode="bold">(n = 73)</content> <content styleCode="bold">%</content> </td><td align="center" styleCode="Rrule" valign="top"><content styleCode="bold">Pentamidine</content> <content styleCode="bold">(n = 71)</content> <content styleCode="bold">%</content> </td></tr><tr styleCode="Botrule"><td align="justify" styleCode="Lrule Rrule" valign="top">Fever </td><td align="center" styleCode="Rrule" valign="top">40 </td><td align="center" styleCode="Rrule" valign="top">25 </td></tr><tr styleCode="Botrule"><td align="justify" styleCode="Lrule Rrule" valign="top">Nausea </td><td align="center" styleCode="Rrule" valign="top">22 </td><td align="center" styleCode="Rrule" valign="top">37 </td></tr><tr styleCode="Botrule"><td align="justify" styleCode="Lrule Rrule" valign="top">Rash </td><td align="center" styleCode="Rrule" valign="top">22 </td><td align="center" styleCode="Rrule" valign="top">13 </td></tr><tr styleCode="Botrule"><td align="justify" styleCode="Lrule Rrule" valign="top">Diarrhea </td><td align="center" styleCode="Rrule" valign="top">21 </td><td align="center" styleCode="Rrule" valign="top">31 </td></tr><tr styleCode="Botrule"><td align="justify" styleCode="Lrule Rrule" valign="top">Insomnia </td><td align="center" styleCode="Rrule" valign="top">19 </td><td align="center" styleCode="Rrule" valign="top">14 </td></tr><tr styleCode="Botrule"><td align="justify" styleCode="Lrule Rrule" valign="top">Headache </td><td align="center" styleCode="Rrule" valign="top">18 </td><td align="center" styleCode="Rrule" valign="top">28 </td></tr><tr styleCode="Botrule"><td align="justify" styleCode="Lrule Rrule" valign="top">Vomiting </td><td align="center" styleCode="Rrule" valign="top">14 </td><td align="center" styleCode="Rrule" valign="top">17 </td></tr><tr styleCode="Botrule"><td align="justify" styleCode="Lrule Rrule" valign="top">Cough </td><td align="center" styleCode="Rrule" valign="top">14 </td><td align="center" styleCode="Rrule" valign="top">1 </td></tr><tr styleCode="Botrule"><td align="justify" styleCode="Lrule Rrule" valign="top">Sweat </td><td align="center" styleCode="Rrule" valign="top">10 </td><td align="center" styleCode="Rrule" valign="top">3 </td></tr><tr><td align="justify" styleCode="Lrule Rrule" valign="top">Monilia, oral </td><td align="center" styleCode="Rrule" valign="top">10 </td><td align="center" styleCode="Rrule" valign="top">3 </td></tr></tbody></table>
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.